NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Core Insights - NeOnc Technologies Holdings, Inc. has signed a definitive Letter of Intent to acquire a Delaware entity co-owned by Dr. Ishwar K. Puri and Beth R. Levinson, focusing on innovative treatments for brain cancers [1] - The transaction is valued at $3.5 million, consisting of $500,000 in cash and $3 million in NeOnc common stock priced at $25 per share [2] - Dr. Ishwar K. Puri will join NeOnc's Board of Directors, bringing extensive experience in research and innovation from his role at the University of Southern California [3][4] Company Overview - NeOnc Technologies is a clinical-stage life sciences company dedicated to developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [5] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials [5]